The company announced the job cuts and a deal to sell its assets to 14ner Oncology for up to $58 million May 30. The drugmaker also will discontinue its preclinical programs.
The decision comes after months of financial struggles for the once-thriving pharmacy company. It recently cut 60 percent of its staff after a phase 2 trial for one of its lead drugs flopped.
The decision will affect its 27 employees. At its peak, the drugmaker employed more than 425 people.
Read the full report here.
More articles on pharmacy:
Viewpoint: The $2.1M drug price record won’t last long
J&J to cut 61 jobs in New Jersey
Mallinckrodt to spin off generics unit
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.